3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
120
Fluorouracil
90
Cetuximab
84
Leucovorin
82
Oxaliplatin
80
pembrolizumab
70
Irinotecan
66
Nivolumab
46
Capecitabine
43
Specimen Handling
40
regorafenib
30
Folfox protocol
29
trifluridine tipiracil drug combination
28
Magnetic Resonance Spectroscopy
27
Biopsy
27
Panitumumab
26
HMPL-013
26
Standard of Care
25
IFL protocol
21
Gemcitabine
20
Blood Specimen Collection
19
tislelizumab
18
atezolizumab
18
Trifluridine
18
Cisplatin
18
balstilimab
16
Colonoscopy
16
Carboplatin
16
encorafenib
15
Paclitaxel
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
tisotumab vedotin
×
1 year
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled